Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−10.01 M USD
0.00 USD
12.10 M
About Akari Therapeutics Plc
Sector
Industry
CEO
Samir R. Patel
Website
Headquarters
Boston
Founded
2004
FIGI
BBG003PMV495
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.
A silent bullish breakout is happening at very low risk This company is mainly for testing clinical tests
Akari Therapeutics Announces Positive Interim Data from Phase IIAKTX: Akari Therapeutics Plc
2020-01-10 09:30:09
Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study
AKTX - thinly traded, low float bio - Long IdeaA lot of folks have been asking me regarding the idea around NASDAQ:AKTX setup. So instead of repeating myself over twitter and other places, I am going to post some DD behind my thesis in case you find it useful.
Currently, stock trades around $2 mark so w/ ~15M shares in the OS, the market cap
High Volatility Short AKTXThis therapeutics company has been known for high marks in the historical volatility department, but now that it's up so high on volume and it's particularly volatile now it could be a good time to short it. NASDAQ:AKTX
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.